Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT06902246 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma

Interventions

DRUG: Regorafenib
RADIATION: TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization

Sponsor

University of Miami

Collaborators

[object Object]